Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
What makes a drug discovery consortium successful?
Consortia are enabling drug discovery in areas that individual organizations are unable to support alone because of the high risk or the need to pool information. This article discusses desirable features that can underpin the success of such consortia.
In the past 15 years, large pharma companies have transitioned from an internally focused research model to community-sourcing, collaborative approaches that are now increasingly driving innovation in drug discovery1,2,3. Such collaborations often begin as one-to-one relationships with a partner organization that performs a high-risk step, such as target validation or lead discovery2,3. In some areas, this type of collaboration has subsequently matured into larger consortia, as increasing numbers of pharma companies have become comfortable with sharing risks, costs and opportunities with each other, as well as with academic groups, thereby pooling funds and resources and also accessing external funding.
Bryans, J. S., Kettleborough, C. A. & Solari, R. Are academic drug discovery efforts receiving more recognition with declining industry efficiency? Expert Opin. Drug Discov.14, 605–607 (2019).
